This is critical given that both first-generation EGFR-TKIs gefitinib and erlotinib have since been widely used as second-line or maintenance treatment after chemotherapy failure in advanced non‐small cell lung cancer as opposed to a first-line treatment in chemotherapy-naïve patients11. The gene discussed is EGFR; the disease is lung cancer.